ArticleJCI insight2020
Computational discovery of therapeutic candidates for preventing preterm birth.
Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Simvastatin and Primaquine Identified as Potential Endometriosis Therapeutics via a Novel Epithelial-Stromal Assembloid Drug Screening Assay.bioRxiv : the preprint server for biology · 2026Article
- Article
- Nestorone, a potent progestin, exhibits anti-inflammatory activity and prevents preterm birth in murine models of premature labor.American journal of obstetrics and gynecology · 2026Article
- Computational discovery of precision therapeutics for hidradenitis suppurativa.bioRxiv : the preprint server for biology · 2026Article
- Multi-tissue miRNA networks in preterm birth: from molecular mechanisms to precision medicine.Frontiers in immunology · 2026Review
- Single-cell-level digital twins for preterm birth prevention strategies.bioRxiv : the preprint server for biology · 2025Article
- Article
- Predicting Spontaneous Preterm Birth Using the Immunome.Clinics in perinatology · 2024Review
- Identifying therapeutic candidates for endometriosis through a transcriptomics-based drug repositioning approach.iScience · 2024Article
- Data-driven insights can transform women's reproductive health.npj women's health · 2024Review
- Transcriptomics-driven drug repositioning for the treatment of diabetic foot ulcer.Scientific reports · 2023Article
- Multifunctional nanoparticle for cancer therapy.MedComm · 2023Review
- Identification of Nifurtimox and Chrysin as Anti-Influenza Virus Agents by Clinical Transcriptome Signature Reversion.International journal of molecular sciences · 2022Article
- Dendrimer-Based N-Acetyl Cysteine Maternal Therapy Ameliorates Placental InflammationFrontiers in bioengineering and biotechnology · 2022Article
- Maternal and Infant Immune Repertoire Sequencing Analysis Identifies Distinct Ig and TCR Development in Term and Preterm Infants.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Next generation strategies for preventing preterm birth.Advanced drug delivery reviews · 2021Review
- Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19.Scientific reports · 2021Article
- Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19.Research square · 2021Article
- Towards personalized medicine in maternal and child health: integrating biologic and social determinants.Pediatric research · 2021Article
- Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak.Viruses · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Few therapeutic methods exist for preventing preterm birth (PTB), or delivery before completing 37 weeks of gestation. In the US, progesterone (P4) supplementation is the only FDA-approved drug for use in preventing recurrent spontaneous PTB. However, P4 has limited effectiveness, working in only approximately one-third of cases. Computational drug repositioning leverages data on existing drugs to discover novel therapeutic uses. We used a rank-based pattern-matching strategy to compare the differential gene expression signature for PTB to differential gene expression drug profiles in the Connectivity Map database and assigned a reversal score to each PTB-drug pair. Eighty-three drugs, including P4, had significantly reversed differential gene expression compared with that found for PTB. Many of these compounds have been evaluated in the context of pregnancy, with 13 belonging to pregnancy category A or B - indicating no known risk in human pregnancy. We focused our validation efforts on lansoprazole, a proton-pump inhibitor, which has a strong reversal score and a good safety profile. We tested lansoprazole in an animal inflammation model using LPS, which showed a significant increase in fetal viability compared with LPS treatment alone. These promising results demonstrate the effectiveness of the computational drug repositioning pipeline to identify compounds that could be effective in preventing PTB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.